Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119822
Chunk: 42

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 42
---
 Semnur Equityholders up to an aggregate of $280.0 million in contingent cash consideration based on the achievement of certain milestones. A $40.0 million payment will be due upon obtaining the first approval of an NDA (as defined below) of any Semnur product, which includes SEMDEXA. Additional payments will be due upon the achievement of certain cumulative net sales of Semnur products, as follows:

| • |     | a $20.0 million payment upon the achievement of $100.0 million in cumulative net sales of a Semnur 
 product;                                                                                           |

| • |     | a $20.0 million payment upon the achievement of $250.0 million in cumulative net sales of a Semnur 
 product;                                                                                           |

| • |     | a $50.0 million payment upon the achievement of $500.0 million in cumulative net sales of a Semnur 
 product; and                                                                                       |

| • |     | a $150.0 million payment upon the achievement of $750.0 million in cumulative net sales of a Semnur 
 product.                                                                                            |

These milestone obligations could impose substantial additional costs on us, divert resources from other aspects of our business, and adversely affect the overall profitability of SEMDEXA, if approved. We may need to obtain additional financing to satisfy these milestone payments, and cannot be sure that any additional funding, if needed, will be available on terms favorable to us, or at all. 28

We will require substantial additional funding, which may not be available to us on acceptable terms, or at all. Our operations have consumed substantial amounts of cash since inception. We expect to significantly increase our spending to continue our commercialization efforts for ZTlido, GLOPERBA and ELYXYB, advance development of our current product candidates and launch and commercialize any product candidates for which we receive regulatory approval. Furthermore, we expect to incur additional costs associated with operating as a public company. We will also require additional capital to fund our other operating expenses and capital expenditures. As of December 31, 2024, our cash and cash equivalents were approximately $3.3 million and we had an accumulated deficit of approximately $563.1 million. The amount and timing of our future funding requirements will depend on many factors, some of which are outside of our control, including but not limited to:

| • |     | the costs and expenses associated with our ongoing commercialization efforts for ZTlido, GLOPER